CAWM
NBIX icon

Capital A Wealth Management’s Neurocrine Biosciences NBIX Stock Holding History

Capital A Wealth Management’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-125
Closed -$17.1K – 849
2024
Q4 		$17.1K Buy
+125
New +$15.5K 0.03% 249

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Capital A Wealth Management's NBIX Position: Q1 2025 in Review

Capital A Wealth Management sold out of Neurocrine Biosciences (NBIX) in Q1 2025, closing a stake of 125 shares — an estimated $17.1K sold.

Capital A Wealth Management first reported a position in NBIX in Q4 2024 and held it in 1 quarter. The position peaked at $17.1K in Q4 2024. 586 funds tracked by Wall St. Rank hold NBIX as of Q1 2025.

  • Capital A Wealth Management reported no remaining Neurocrine Biosciences position as of Q1 2025 after selling out during the quarter.
  • Capital A Wealth Management sold 125 Neurocrine Biosciences shares in Q1 2025, an estimated $17.1K.
  • Capital A Wealth Management first reported a position in Neurocrine Biosciences in Q4 2024 and held it in 1 quarter.
  • Capital A Wealth Management's Neurocrine Biosciences position peaked at $17.1K in Q4 2024.
  • 586 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q1 2025.

Based on Capital A Wealth Management's 13F filing for Q1 2025, filed 2 May 2025.